

Certificate of Analysis

Live Cell count	1.9 million per vial
Viability	94%
CD8+	100%
CD8+ Neg Tetramer+	0.5%
CD8+MART-1 Tetramer+	98.7%
Sterility	Negative for Bacteria, Yeast, and Fungi

Donor Information


Donor ID	358
Age	52
Gender	Female
Race	Caucasian
Height	5'6"
Weight	230
ABO Type	O negative

HLA typing

	Allele 1	Allele 2
HLA-A	*0201	*0201
HLA-B	*44	*15
HLA-C	*03	*05
HLA-DRB1	*0103	*0404

Donors are tested for the blood borne pathogens HIV-1 and 2, Hepatitis B, Hepatitis C and HTLV-1 and are negative. Cells should still be handled as if potentially infectious following biosafety level 2 procedures


FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.



Negative tetramer = HLA-A*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA); MART-1 tetramer = MART-126-35 A27L peptide (ELAGIGILTV)/ HLA-A*0201-PE iTag MHC Tetramer (MBL International, Woburn, MA)

IFN-gamma Secretion

4804JY20 MART-1



20,000 T cells were plated in a 96-well round-bottom plate alone or in the presence of 10,000 T2 cells, a B-LCL expressing HLA-A*0201) alone or in the presence of increasing concentrations HLA-A*0201 restricted native MART-127-35 nonamer peptide (AAGIGILTV), analog (A27L) MART-126-35 decamer peptide (ELAGIGILTV) or HLA-A*0201 restricted WT-1 (RMFPNAPYL). Culture media used is RPMI 1640 + 10% FBS. Supernatants were collected after 18-24 hours of incubation. IFN- γ concentration was analyzed using the Meso Scale Discovery IFN- γ assay.

FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.